Jon Travers

Company: Ipsen

Job title: Senior Director, External Innovation & Early Development

Seminars:

ADC Licensing, Partnering & Investment Session 3:00 pm

It’s no secret that ADCs have firmly positioned themselves at the forefront of oncology R&D and dealmaking. The total value of ADCs peaked at $167 billion in 2023, representing rampant billion-dollar partnerships and M&As from Pfizer, AbbVie, J&J, Merck, Genmab, Ipsen and beyond, and a bulk of Series A VC transactions highlighting a boom of…Read more

day: Pre-Conference Seminar Day Pt 2